CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquires WIL Research

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired WIL Research for approximately $585 million in cash (purchase price $604.8 million including assumed liabilities), a transaction completed in April 2016, structured as all cash.

WIL Research operates in Discovery and Safety Assessment (DSA), is based in United States (global operations). WIL Research was a premier provider of safety assessment and contract development and manufacturing (CDMO) services to biopharmaceutical and agricultural and industrial chemical companies worldwide.

The acquisition enhanced our position as a leading global early-stage CRO by strengthening our ability to partner with clients across the drug discovery and development continuum.

Expected non-GAAP EPS accretion of at least $0.20 in 2016 and $0.45-$0.50 in 2017 Discovery and Safety Assessment (DSA) segment

In addition to enhancing our value proposition for clients, we believe that the acquisition of WIL Research will generate value for shareholders, driving profitable revenue growth and non-GAAP earnings per share accretion of at least $0.20 in 2016 and $0.45 to $0.50 in 2017.James C. Foster, Chairman, President and Chief Executive Officer, Charles River Laboratories

Advisory firms were not disclosed for this transaction.

You're subscribed.

Thanks for signing up.